SG11202007535VA - Thioredoxin reductase inhibitors for use in the treatment of cancer - Google Patents
Thioredoxin reductase inhibitors for use in the treatment of cancerInfo
- Publication number
- SG11202007535VA SG11202007535VA SG11202007535VA SG11202007535VA SG11202007535VA SG 11202007535V A SG11202007535V A SG 11202007535VA SG 11202007535V A SG11202007535V A SG 11202007535VA SG 11202007535V A SG11202007535V A SG 11202007535VA SG 11202007535V A SG11202007535V A SG 11202007535VA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- reductase inhibitors
- thioredoxin reductase
- thioredoxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1802264.0A GB201802264D0 (en) | 2018-02-12 | 2018-02-12 | Cancer treatments |
GBGB1807415.3A GB201807415D0 (en) | 2018-05-04 | 2018-05-04 | Cancer treatments |
PCT/EP2019/053444 WO2019155086A1 (en) | 2018-02-12 | 2019-02-12 | Thioredoxin reductase inhibitors for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007535VA true SG11202007535VA (en) | 2020-09-29 |
Family
ID=65365977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007535VA SG11202007535VA (en) | 2018-02-12 | 2019-02-12 | Thioredoxin reductase inhibitors for use in the treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210038577A1 (en) |
EP (1) | EP3752151A1 (en) |
JP (1) | JP2021513573A (en) |
CN (1) | CN111867587A (en) |
AU (1) | AU2019219322A1 (en) |
BR (1) | BR112020016265A2 (en) |
CA (1) | CA3091085A1 (en) |
IL (1) | IL276668A (en) |
MA (1) | MA51821A (en) |
RU (1) | RU2020126540A (en) |
SG (1) | SG11202007535VA (en) |
WO (1) | WO2019155086A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021014812A1 (en) * | 2019-07-24 | 2021-01-28 | 国立大学法人東海国立大学機構 | Treatment for fibroblastic or myofibroblastic tumor and disease |
WO2023017149A1 (en) * | 2021-08-13 | 2023-02-16 | Oblique Therapeutics Ab | Thioredoxin 1 antibodies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169973A (en) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | Treatment of breast cancer with iodonitrobenzamides in combination with anti-tumor agents |
EP2595618A1 (en) * | 2010-07-19 | 2013-05-29 | BiPar Sciences, Inc. | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
US10849862B2 (en) * | 2014-12-26 | 2020-12-01 | Theravalues Corporation | Formulation of curcumin and anti-PD-1 antibody |
GB201514015D0 (en) * | 2015-08-07 | 2015-09-23 | Arnér Elias S J And Dept Of Health And Human Services | Novel pyridazinones and their use in the treatment of cancer |
GB201514018D0 (en) * | 2015-08-07 | 2015-09-23 | Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic | Novel tricyclic compounds and their use in the treatment of cancer |
GB201514021D0 (en) * | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
JP2020507625A (en) * | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
MX2019009356A (en) * | 2017-02-07 | 2019-09-19 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer. |
MX2019009266A (en) * | 2017-02-07 | 2019-11-05 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer. |
KR20190115012A (en) * | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | Heterocyclylsulfonyl-substituted pyridine and its use in the treatment of cancer |
US20200113852A1 (en) * | 2017-06-22 | 2020-04-16 | Triact Therapeutics, Inc. | Methods of patient selection and treating trxr- or prdx-overexpressed cancers |
US11220544B2 (en) * | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
EP3700551A4 (en) * | 2017-10-25 | 2021-10-13 | Dana-Farber Cancer Institute, Inc. | Cancer vaccine compositions and methods for using same to treat cancer |
-
2019
- 2019-02-12 WO PCT/EP2019/053444 patent/WO2019155086A1/en unknown
- 2019-02-12 EP EP19704619.6A patent/EP3752151A1/en not_active Withdrawn
- 2019-02-12 CA CA3091085A patent/CA3091085A1/en active Pending
- 2019-02-12 MA MA051821A patent/MA51821A/en unknown
- 2019-02-12 RU RU2020126540A patent/RU2020126540A/en unknown
- 2019-02-12 AU AU2019219322A patent/AU2019219322A1/en active Pending
- 2019-02-12 CN CN201980019617.9A patent/CN111867587A/en active Pending
- 2019-02-12 BR BR112020016265-5A patent/BR112020016265A2/en not_active IP Right Cessation
- 2019-02-12 JP JP2020565544A patent/JP2021513573A/en active Pending
- 2019-02-12 SG SG11202007535VA patent/SG11202007535VA/en unknown
- 2019-02-12 US US16/969,165 patent/US20210038577A1/en not_active Abandoned
-
2020
- 2020-08-12 IL IL276668A patent/IL276668A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019155086A1 (en) | 2019-08-15 |
IL276668A (en) | 2020-09-30 |
RU2020126540A (en) | 2022-03-14 |
CN111867587A (en) | 2020-10-30 |
AU2019219322A1 (en) | 2020-09-10 |
EP3752151A1 (en) | 2020-12-23 |
CA3091085A1 (en) | 2019-08-15 |
BR112020016265A2 (en) | 2020-12-15 |
US20210038577A1 (en) | 2021-02-11 |
JP2021513573A (en) | 2021-05-27 |
MA51821A (en) | 2020-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
HK1249524A1 (en) | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers | |
HRP20180876T1 (en) | Duocarmycin adcs for use in the treatment of bladder cancer | |
IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
EP4010080C0 (en) | Heterocyclic compounds for use in the treatment of cancer | |
DK3148532T3 (en) | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer | |
HK1259545A1 (en) | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer | |
SI3534885T1 (en) | Farnesyltransferase inhibitors for use in treating cancer | |
IL247586A0 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
IL276668A (en) | Thioredoxin reductase inhibitors for use in the treatment of cancer | |
IL283885A (en) | Cxcr7 inhibitors for the treatment of cancer | |
ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
EP3440052C0 (en) | Compounds for use in the treatment of cancer | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
EP3349731A4 (en) | Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer | |
EP3790895A4 (en) | Ccl21 and checkpoint inhibitors for the treatment of cancer | |
IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
IL283687A (en) | Usp19 inhibitors for use in therapy | |
EP3126520A4 (en) | Biomarkers and use of met inhibitor for treatment of cancer | |
HUP1900281A1 (en) | Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer | |
ZA202001435B (en) | Abx196 for use in the treatment of bladder cancer | |
ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
LT3413894T (en) | Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren`s syndrome |